Cellectis, which is developing cancer immunotherapies based on gene-edited CAR T-cells, announced terms for its US offering on Wednesday.
The Paris, France-based company plans to raise $129 million by offering 3.5 million ADSs. Its shares currently trade on the Alternext market of the Euronext Paris under the symbol ALCLS and its last share price was €35, or $36.83. At that price, Cellectis would command a market value of $1.2 billion.
Recent cancer immunotherapy biotech IPOs include Juno Therapeutics (JUNO; +122%), Kite Pharma (KITE; +274%) and Bellicum Pharmaceuticals (BLCM; +31%).
The company is backed by both Pfizer (NYSE: PFE) and the French government.
Cellectis, which was founded in 2000, plans to list on the NASDAQ under the symbol CLLS. BofA Merrill Lynch, Jefferies and Piper Jaffray are the joint bookrunners on the deal. It is expected to price during the week of March 23, 2015.
